Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

The package remained heavily equity-driven, with 306,406 RSUs and performance stock options tied to long-term results. ・Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last ...

Hims & Hers shares fell 15% after first-quarter earnings miss. Company posted a surprise loss tied to GLP-1 restructuring ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership ...

Shares of Hims & Hers (NYSE:HIMS) dropped roughly 16% in premarket trading on Tuesday after the company reported an ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, saw its stock surge 8% on Friday, May 30th, following the announcement of a 4% workforce reduction. This adjustment comes as the company adapts ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 17 cents ...

HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and ...

Hims & Hers (HIMS) stock dropped 9.75% after hours as Q1 losses widened and margins compressed, offsetting revenue gains and ...